NASDAQ:SAVA Cassava Sciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cassava Sciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.47 +1.76 (+18.13 %) (As of 09/28/2020 06:31 AM ET) Add Compare Share Today's Range$9.82Now: $11.47▼$12.3450-Day Range$2.92MA: $4.44▼$10.4552-Week Range$1.05Now: $11.47▼$12.34Volume13.90 million shsAverage Volume4.75 million shsMarket Capitalization$285.82 millionP/E RatioN/ADividend YieldN/ABeta2.85 ProfileAnalyst RatingsChartCompetitorsDividendEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Cassava Sciences has a forecasted upside of 48.2% from its current price of $11.47.Amount of Analyst CoverageCassava Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCassava Sciences has received 54 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCassava Sciences has received 56 “underperform” votes. (Add your “underperform” vote.)Community SentimentCassava Sciences has received 50.91% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cassava Sciences and other stocks. Vote “Outperform” if you believe SAVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SAVA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,657,959.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 13.70% of the stock of Cassava Sciences is held by insiders.Percentage Held by InstitutionsOnly 24.07% of the stock of Cassava Sciences is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to decrease in the coming year, from ($0.26) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -52.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -52.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 11.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.80 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SAVA Previous Symbol CUSIPN/A CIKN/A Webwww.cassavasciences.com Phone512-501-2444Debt Debt-to-Equity RatioN/A Current Ratio19.36 Quick Ratio19.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book11.36Profitability EPS (Most Recent Fiscal Year)($0.27) Net Income$-4,630,000.00 Net MarginsN/A Return on Equity-20.32% Return on Assets-19.28%Miscellaneous Employees9 Outstanding Shares24,919,000Market Cap$285.82 million Next Earnings Date11/3/2020 (Estimated) OptionableNot Optionable $11.47 +1.76 (+18.13 %) (As of 09/28/2020 06:31 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SAVA News and Ratings via Email Sign-up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Cassava Sciences (NASDAQ:SAVA) Frequently Asked Questions How has Cassava Sciences' stock been impacted by COVID-19? Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SAVA shares have increased by 170.5% and is now trading at $11.47. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cassava Sciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cassava Sciences. When is Cassava Sciences' next earnings date? Cassava Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Cassava Sciences. How were Cassava Sciences' earnings last quarter? Cassava Sciences Inc (NASDAQ:SAVA) released its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.01. View Cassava Sciences' earnings history. When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work? Cassava Sciences shares reverse split on the morning of Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split. What price target have analysts set for SAVA? 2 brokerages have issued 12 month price targets for Cassava Sciences' stock. Their forecasts range from $14.00 to $20.00. On average, they anticipate Cassava Sciences' stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 48.2% from the stock's current price. View analysts' price targets for Cassava Sciences. Who are some of Cassava Sciences' key competitors? Some companies that are related to Cassava Sciences include Repare Therapeutics (RPTX), NGM Biopharmaceuticals (NGM), Legend Biotech (AMTI), Akero Therapeutics (AKRO), Karyopharm Therapeutics (KPTI), Innoviva (INVA), Kiniksa Pharmaceuticals (KNSA), Supernus Pharmaceuticals (SUPN), Esperion Therapeutics (ESPR), Nabriva Therapeutics (NBRV), Athenex (ATNX), Rhythm Pharmaceuticals (RYTM), Phathom Pharmaceuticals (PHAT), Theravance Biopharma (TBPH) and Nkarta (NKTX). View all competitors. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Advanced Micro Devices (AMD), Novavax (NVAX), DURECT (DRRX), Sorrento Therapeutics (SRNE), Tesla (TSLA), NIO (NIO), Opko Health (OPK) and Alibaba Group (BABA). Who are Cassava Sciences' key executives? Cassava Sciences' management team includes the following people: Mr. Remi Barbier, Founder, Chairman, CEO & Pres (Age 59)Mr. Eric J. Schoen, Chief Financial Officer (Age 51)Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 76)Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs What is Cassava Sciences' stock symbol? Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA." Who are Cassava Sciences' major shareholders? Cassava Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (0.55%), Nuveen Asset Management LLC (0.50%), Jefferies Group LLC (0.40%), Jane Street Group LLC (0.38%), Charles Schwab Investment Management Inc. (0.20%) and New York State Common Retirement Fund (0.13%). Company insiders that own Cassava Sciences stock include Armistice Capital Master Fund, Eric Schoen, Remi Barbier and Sanford Robertson. View institutional ownership trends for Cassava Sciences. Which institutional investors are selling Cassava Sciences stock? SAVA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Bank of Montreal Can. View insider buying and selling activity for Cassava Sciences. Which institutional investors are buying Cassava Sciences stock? SAVA stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Jane Street Group LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., New York State Common Retirement Fund, WINTON GROUP Ltd, Jefferies Group LLC, and American International Group Inc.. Company insiders that have bought Cassava Sciences stock in the last two years include Eric Schoen, Remi Barbier, and Sanford Robertson. View insider buying and selling activity for Cassava Sciences. How do I buy shares of Cassava Sciences? Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cassava Sciences' stock price today? One share of SAVA stock can currently be purchased for approximately $11.47. How big of a company is Cassava Sciences? Cassava Sciences has a market capitalization of $285.82 million. The company earns $-4,630,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Cassava Sciences employs 9 workers across the globe. What is Cassava Sciences' official website? The official website for Cassava Sciences is www.cassavasciences.com. How can I contact Cassava Sciences? Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected] This page was last updated on 9/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
